Provided by Tiger Fintech (Singapore) Pte. Ltd.

Jasper Therapeutics

5.26
-0.1500-2.77%
Post-market: 5.260.00000.00%18:44 EDT
Volume:172.16K
Turnover:919.36K
Market Cap:79.02M
PE:-1.00
High:5.51
Open:5.41
Low:5.23
Close:5.41
Loading ...
May 12, 2023

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
May 03, 2023

Correspondence

Form CORRESP - Correspondence
Apr 14, 2023

Major Issues Report

8-K - Current report
Apr 14, 2023

Proposed Sale Of Securities

144 - Report of proposed sale of securities
Apr 13, 2023

Proposed Sale Of Securities

144 - Report of proposed sale of securities
Apr 13, 2023

Proposed Sale Of Securities

144 - Report of proposed sale of securities
Mar 08, 2023

Major Issues Report

8-K - Current report
Mar 08, 2023

Annual Report

10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Mar 08, 2023

Employee Stock Ownership

S-8 - Securities to be offered to employees in employee benefit plans
Feb 27, 2023

Beneficial Ownership Change

SC 13D - General statement of acquisition of beneficial ownership
Feb 17, 2023

Major Issues Report

8-K - Current report
Feb 16, 2023

Major Issues Report

8-K - Current report
Feb 14, 2023

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 13, 2023

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 10, 2023

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 06, 2023

Beneficial Ownership Change

SC 13G - Statement of acquisition of beneficial ownership by individuals
Jan 31, 2023

Beneficial Ownership Change

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
Jan 30, 2023

Beneficial Ownership Change

SC 13G - Statement of acquisition of beneficial ownership by individuals
Jan 27, 2023

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Jan 27, 2023

Major Issues Report

8-K - Current report